Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingSAN.PA
Biotech & Genomic Medicine▼
AbbVie Takes On $8 Billion in Debt to Fund Apogee Therapeutics Acquisition
AbbVie is taking on $8 billion in debt to finance its $10.6 billion acquisition of Apogee Therapeutics, a deal expected to close in the third quarter pending regulatory approvals. The company said the acquisition will not boost adjusted earnings per share until 2032 and will cause $0.14 in dilution this year, lowering its adjusted EPS guidance to a range of $13.87 to $14.07. AbbVie plans to maintain its dividend, having raised it by 5.5% to $1.73 per share this year, and aims to preserve its A2/A- credit rating while reducing net leverage to about 2 times within two to three years after closing. The deal is centered on Apogee's lead drug candidate, Zumilokibart, a monoclonal antibody targeting interleukin-13 for atopic dermatitis with a three- to six-month dosing interval that could compete with Sanofi's Dupixent, which generated 15.7 billion euros in 2025 sales. AbbVie reported second-quarter revenue of $16.9 billion, up 10.2%, and earnings per share of $2.03, a 290% increase from the prior year.
Biotech Stocks Hit 52-Week Highs on Earnings and Pipeline Progress
Several biotech stocks reached 52-week highs on August 7, 2026, driven by quarterly results and clinical advancements. Delcath Systems surged over 22% to $15.62 after reporting second-quarter net revenues of $29.1 million, up from $24.2 million a year earlier, with HEPZATO product revenue growing about 30% to $27.1 million across roughly 31 active treatment centers. Alto Neuroscience rose to a 52-week high of $29.48 following last month's registered direct offering that raised an estimated $100 million to advance its lead candidate ALTO-207 toward a Phase 3 trial. Hemab Therapeutics hit $53.60 after positive Phase 2 data showed Sutacimig reduced the mean annualized treated bleeding rate by 84% in Glanzmann thrombasthenia and Factor VIII deficiency, alongside encouraging interim Phase 2 results for HMB-002 in Von Willebrand's disease. Monopar Therapeutics reached $124.31 on the back of positive Phase 3 results for ALXN1840 in Wilson disease, which earned a Rare Pediatric Disease voucher from the FDA, with an NDA submission planned by mid-2026. Nurix Therapeutics climbed to $25.49 after receiving a $10 million milestone payment from Sanofi for the Phase 1 initiation of NX-3911 and announcing with Roche the first patient enrolled in the Phase 3 DAYBreak CLL-306 trial evaluating Bexobrutideg in relapsed/refractory chronic lymphocytic leukemia.
Novavax Raises 2026 Revenue Guidance to $235-$275 Million on Matrix-M Demand
Novavax raised its full-year 2026 revenue guidance to between $235 million and $275 million, driven by strong demand for its Matrix-M adjuvant from commercial partners. The company reported a net loss of $53 million in the second quarter on total revenue of $57 million, a sharp decline from $239 million a year earlier due to the absence of one-time milestone payments. Novavax is on track to reduce operating expenses by approximately 90% from peak levels and reiterated its goal of reaching non-GAAP profitability as early as 2028. The Sanofi partnership is advancing, with Sanofi in advanced regulatory discussions for a Phase 3 combination COVID-19/influenza vaccine study, which would trigger a $125 million milestone payment. Novavax also expects a $75 million manufacturing tech transfer milestone from Sanofi by mid-2027, extending its cash runway into 2029.
Nurix Therapeutics Receives $10 Million Milestone as Phase 3 Trial Begins
Nurix Therapeutics announced a $10 million milestone payment from Sanofi triggered by the first-in-human trial of an oral STAT6 degrader, bringing total receipts under that collaboration to about $139 million. The company also enrolled the first patient in a pivotal global Phase 3 trial of bexobrutideg for relapsed or refractory chronic lymphocytic leukemia, conducted in partnership with Roche. The Sanofi deal leaves Nurix eligible for roughly $453 million in additional milestones plus potential royalties, while the Roche-partnered study marks a move into registrational testing. Both programs advance Nurix's clinical pipeline in targeted protein degradation and signal that large pharmaceutical partners are committing resources to its drug candidates.
NAD Finds Some DUPIXENT Claims Supported, Recommends Sanofi Modify or Discontinue Others
The National Advertising Division found certain claims for Sanofi’s eczema treatment DUPIXENT supported but recommended the company modify or discontinue other claims following a challenge by Galderma. NAD determined that claims about staying ahead of eczema, blocking a key source of inflammation, healing skin from within, and 90% clearer skin were supported, while an animated mechanism-of-action video likely conveyed an unsupported message. The division recommended that Sanofi modify or discontinue television claims about long-lasting clearer skin and fast itch relief to clearly disclose how many patients achieved the results or that the results reflected treatment with DUPIXENT combined with topical corticosteroids. NAD also found that a prescriber-facing claim of itch reduction starting as early as day 2 was not supported by the post hoc analysis and should be discontinued or modified. Sanofi stated it will comply with NAD’s recommendations.
Sanofi’s MenQuadfi approved in EU for infants from six weeks of age
The European Commission has approved Sanofi’s MenQuadfi vaccine for use in infants aged six weeks and older, expanding protection against invasive meningococcal disease caused by serogroups A, C, W and Y. MenQuadfi was previously authorized in the EU only for individuals 12 months and older, and the new indication introduces infant dosing schedules aligned with routine pediatric immunization programs. The approval is supported by the MET58 pivotal study, which evaluated immunogenicity, safety and tolerability in more than 6,000 infants across 11 countries. The decision broadens Sanofi’s vaccine portfolio and gives healthcare providers an additional option to protect infants against a rapidly progressing disease associated with high mortality and long-term complications.
Sanofi Ends Amlitelimab Development for Atopic Dermatitis After Pipeline Review
Sanofi has discontinued development of amlitelimab for atopic dermatitis following a pipeline review. The decision was based on an assessment of efficacy and safety data that indicated no meaningful improvement over current treatments. This move affects a key immunology asset and will influence how Sanofi sets its future research and development priorities. Atopic dermatitis is an important area for many drug makers given ongoing patient needs and existing biologic therapies, and this decision removes one potential future option from Sanofi's immunology portfolio.
Sanofi reports €1 billion impairment and completes €1 billion buyback
Sanofi reported €1,031 million of intangible asset impairments for the second quarter of 2026 and completed a €1,009 million share buyback covering 1.05% of its share count. The most followed narrative points to a fair value of €96.70, implying the stock is 23% undervalued compared with its last close of €74.47. The valuation case rests on steady top-line growth, rising margins, and a lower future earnings multiple, supported by innovative product launches and a strong R&D pipeline that includes multiple Phase III readouts through 2026 and expansion of biologics such as Dupixent and amlitelimab. Key risks include intensifying pricing pressure in vaccines and potential failures of late-stage pipeline assets.
Alnylam Amvuttra Revenue Surpasses $1 Billion in a Quarter for the First Time
Alnylam Pharmaceuticals reported that its drug Amvuttra exceeded $1 billion in global net product revenues in a single quarter for the first time, reaching $1.03 billion in the second quarter of 2026. Total global net product revenues were approximately $1.2 billion, a 74% increase compared to the same period last year. The company revised its full-year 2026 total net product revenue guidance to a range of $4.7 billion to $5.1 billion, citing a normalization of second-line demand growth. Non-GAAP operating income more than tripled to $318 million, while gross margin on product sales declined to 75%, down four percentage points year-over-year due to higher royalties payable to Sanofi. Alnylam also announced a strategic collaboration with B1 for exclusive commercialization and distribution rights for Amvuttra in mainland China and Macau.
Sanofi Beats Q2 Earnings and Sales Estimates but Shares Fall on Pipeline Setbacks
Sanofi reported second-quarter 2026 adjusted earnings of $1.22 per American depositary share, beating the Zacks Consensus Estimate of $1.10, while revenues of $13.48 billion surpassed the $12.73 billion consensus. Blockbuster drug Dupixent saw sales climb 37.6 percent at constant exchange rates to €5.15 billion, crossing the €5 billion quarterly mark for the first time, and the company raised its full-year 2026 sales growth outlook to around 10 percent at constant exchange rates. However, the quarter included notable pipeline setbacks, including the decision not to advance amlitelimab to regulatory submission and the discontinuation of itepekimab in chronic obstructive pulmonary disease and chronic rhinosinusitis, along with balinatunfib studies in Crohn's disease and ulcerative colitis. These setbacks resulted in more than €200 million of wind-down costs and a €952 million impairment related to amlitelimab, and despite the better-than-expected results and improved outlook, Sanofi's shares were down around 6 percent in pre-market trading.
Inflammatory Bowel Disease Market to Reach USD 21 Billion in 2025, Driven by Next-Generation Therapies
The inflammatory bowel disease market across the seven major markets was valued at USD 21 billion in 2025, with the United States accounting for the largest share. The total number of incident cases of inflammatory bowel disease in the seven major markets was around 181 million in 2025. Growth is being fueled by the rising prevalence of Crohn's disease and ulcerative colitis, increased adoption of advanced biologic therapies, and the emergence of novel mechanisms of action targeting IL-23, TL1A, and S1P pathways. Key pipeline candidates include Abivax's ABX464, Merck's Tulisokibart, RedHill Biopharma's RHB-204, and Teva Pharmaceuticals and Sanofi's duvakitug, among others. The anticipated launch of these next-generation therapies is expected to reshape the treatment landscape and address unmet needs in biologic-refractory patients.
Regeneron beats quarterly estimates on eczema drug strength, shares rise
Regeneron beat Wall Street estimates for second-quarter revenue and profit, driven by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Global net sales of Dupixent, recorded by partner Sanofi, increased 38% to about $6 billion, surpassing estimates of $5.34 billion. Quarterly U.S. sales of the high-dose Eylea rose 52% to $596 million, while the lower-dose version faced competitive pressures. The company fully repaid the Sanofi Development Balance, which RBC Capital Markets analyst Brian Abrahams said should improve margins and make second-half numbers look much better. Quarterly revenue rose 17% to $4.29 billion, exceeding estimates of $3.82 billion, and non-GAAP adjusted profit was $14.29 per share, beating the estimate of $10.26.
Sanofi Offers 5.6% Dividend Yield and Promising Growth Pipeline
Sanofi, the French pharmaceutical company, offers a 5.6% dividend yield and a total shareholder yield approaching 11% when including stock buybacks. Its top drug Dupixent saw first-quarter sales grow 31% year over year, driving overall sales up 13.6%. The stock trades at a forward price-to-earnings ratio of 9, below its five-year average of 11, and has fallen nearly 15% over the past year. Sanofi also reported five regulatory approvals in immunology during the quarter and has a pipeline of drugs in development that could offset future patent expirations.
Teva's duvakitug could drive another 50% surge as turnaround gains momentum
Teva Pharmaceutical Industries' shift from generic to branded drugs has driven an 85% share price surge over the past 12 months, and its pipeline candidate duvakitug could fuel another 50% rally. Branded drugs like Austedo, Ajovy, and Uzedy are growing sales at mid-double-digit rates, while generics now account for just over half of total revenue. Management expects 2026 earnings per share between $1.91 and $2.11, down from $2.65 in 2025 due to the dilutive impact of the Emalex Biosciences acquisition, but forecasts a 30% increase in operating profit and adjusted EBITDA starting next year. Duvakitug, co-developed with Sanofi for ulcerative colitis and Crohn's disease, is entering phase 3 trials after promising phase 2b results, with peak annual sales projected at $2 billion to $5 billion. With the stock trading at less than 10 times estimated 2027 earnings, further progress on duvakitug could trigger another major rally.
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
Scribe Therapeutics surged 67% on Friday after raising $128.7 million in an upsized initial public offering. The Alameda, California-based clinical-stage gene therapy developer opened at $25 per share, significantly above its $15 IPO price, after selling 8.58 million shares, up from the initially marketed 7.15 million shares at between $13 and $15 each. The first-day trading level gave the company a market value of approximately $440.3 million. Sanofi SA agreed through affiliates to purchase about $7.5 million of shares at the IPO price in a concurrent private placement, while existing backer Eli Lilly indicated interest in owning up to 11% of the company post-offering. Scribe, which is evaluating gene-editing technologies for atherosclerotic cardiovascular disease and expects initial trial data in the first half of 2027, reported a net loss of $17.4 million on collaboration revenue of $2.2 million for the three months ended March 31. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo led the IPO.
Sanofi halts amlitelimab development for atopic dermatitis, will not seek global regulatory approvals
Sanofi has decided to discontinue clinical development of amlitelimab for moderate-to-severe atopic dermatitis and will not submit the anti-OX40L monoclonal antibody for global regulatory evaluations. The company determined that the totality of efficacy and safety data does not support further development in this indication, as amlitelimab would not represent a meaningful improvement over standard of care despite long-term response maintenance and an emerging safety profile seen in the Phase 3 ESTUARY extension study. Sanofi will work with investigators and regulators to gradually close ongoing atopic dermatitis studies while ensuring appropriate care transitions for enrolled patients. The company reaffirmed its 2026 financial guidance and noted that a Phase 2 study of amlitelimab in celiac disease remains ongoing with results expected in the second half of 2026.
Sanofi reshapes Executive Committee ahead of next strategic chapter
Sanofi announced an evolution of its Executive Committee effective September 1, 2026, bringing together a focused leadership team as the company prepares its next strategic chapter. The new committee includes François Roger as Executive Vice President of Finance, Paulo Fontoura as Executive Vice President and Head of Research & Development, Manuela Buxo as Executive Vice President of Specialty Care, Thomas Triomphe as Executive Vice President of Vaccines, Thomas Grenier as Executive Vice President of General Medicines, Brendan O'Callaghan as Executive Vice President of Manufacturing & Supply, Jamie Haney as Executive Vice President and General Counsel, and Véronique Jaillet as Executive Vice President and Chief People Officer ad interim. Emmanuel Frenehard, Head of Digital, and Audrey Duval, Head of Corporate Affairs, will continue to report directly to CEO Belén Garijo. Madeleine Roach, currently Head of Business Operations, will become President and Country Lead of Sanofi Germany, Switzerland and Austria, while her current responsibilities will be integrated into the Finance function, which will also gain Global Partnering and Business Development. Thomas Triomphe will additionally assume responsibility for China. Olivier Charmeil, currently Executive Vice President of General Medicines, will transition to Strategic Projects Advisor to the CEO, and Roy Papatheodorou, currently Executive Vice President and General Counsel, has decided to leave the organization.
Aqemia and Sanofi expand research collaboration with new target nomination
Aqemia and Sanofi have expanded their multi-year research collaboration with the nomination of a new therapeutic target and an additional milestone payment. The partnership, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. Aqemia uses its proprietary physics-based generative AI platform, Qemi, to design novel molecules for Sanofi's targets, while Sanofi leads wet lab research, development, and commercialization. The collaboration now spans teams in Paris, London, Boston, and Frankfurt, and the new target nomination reflects growing confidence in the platform's ability to tackle difficult, first-in-class projects.
Three High-Yield Healthcare Dividend Stocks Worth Holding
Pfizer, Novo Nordisk, and Sanofi are highlighted as high-yield dividend stocks to buy and hold despite recent challenges. Pfizer offers a forward dividend yield of 7.1% and is expected to benefit from products like Padcev and Abrysvo, along with a promising pipeline in oncology and weight loss. Novo Nordisk, with a 3.6% forward yield, remains a leader in diabetes and weight loss markets and is advancing candidates such as zenagamtide and CagriSema, while also diversifying into rare blood diseases. Sanofi provides a 5.6% forward yield, driven by the strong performance of Dupixent and pipeline prospects like frexalimab, which could generate over $1 billion in peak annual sales.
Global Vaccine Sales Market to Reach US$141.40 Billion by 2036
The global vaccine sales market is projected to grow from US$76.40 billion in 2026 to US$141.40 billion by 2036, expanding at a compound annual growth rate of 6.3%. Growth is supported by rising infectious disease prevalence, broader government-funded immunisation programmes in low- and middle-income countries, and sustained investment in mRNA, viral vector, DNA and needle-free vaccine technologies. Platform-based technologies are enabling developers to pursue multiple disease targets, with programmes such as Moderna and Merck's mRNA-4157 illustrating the expanding role of mRNA in oncology. In December 2025, the Coalition for Epidemic Preparedness Innovations committed up to US$54.3 million to support a Phase III trial of Moderna's mRNA-based H5 pandemic influenza vaccine candidate, advancing the first mRNA influenza vaccine into pivotal-stage development. The market remains sensitive to U.S. tariff policies and supply-chain pressures, prompting companies to localise manufacturing and diversify suppliers. Key players include GSK, Pfizer, Sanofi, Moderna, Merck, BioNTech, AstraZeneca and Serum Institute of India, with the report profiling 21 companies in total.
Sanofi Could Be 21% Undervalued After FDA Clears Sarclisa Escena
Sanofi stock may be undervalued by about 21% following US FDA approval of Sarclisa Escena, a subcutaneous multiple myeloma treatment that can be administered via on-body injector or manual injection. The most widely followed fair value estimate stands at €96.70 per share, well above the recent price of €76.23, even as the stock has slipped 4.94% over the past 90 days and 7.40% year-to-date. Supporters point to Sanofi's innovative pipeline, including Dupixent and amlitelimab, and multiple Phase III readouts through 2026 as drivers of long-term sales and earnings. Risks include vaccine pricing pressure and mixed late-stage trial results that could undermine the upbeat valuation case.
FDA approves Sanofi’s Sarclisa Escena as first anticancer treatment via on-body injector
The US Food and Drug Administration has approved Sanofi’s subcutaneous Sarclisa Escena for all existing multiple myeloma indications of the intravenous formulation, making it the first anticancer treatment administered through an on-body injector. The approval covers use in combination with standard-of-care regimens and is supported by the pivotal IRAKLIA phase 3 study, which showed comparable efficacy and safety to intravenous Sarclisa, with significantly shorter treatment time and fewer infusion-related reactions. In the IRAKLIA study, Sarclisa Escena via the CirCLIQ on-body injector combined with pomalidomide and dexamethasone achieved a 71.1% objective response rate versus 70.5% for the intravenous arm, while systemic administration reactions occurred in 1.5% of patients compared to 25% with intravenous infusion. The on-body injector, developed using Enable Injections’ enFuse platform, uses a retractable 30-gauge needle and is designed to deliver high-volume medicines subcutaneously with the push of a button, potentially reducing physical burden on nurses and allowing more patient interaction. Sarclisa is approved in nearly 60 countries and has been prescribed to more than 70,000 patients worldwide.
UBS backs European pharma as cleaner alternative to AI trade
UBS has reiterated its overweight stance on European pharmaceuticals, framing the sector as a more resilient home for capital than artificial intelligence at a point when the wider market is slowing. The bank argued that the investment case now rests on more than defensive quality, pointing to improving earnings revisions, low relative valuations and lighter ownership after the sector became a source of funds earlier this year. European pharma has risen more than 5% since mid-June, making it the best-performing sector over that period, and UBS described the shift as the 'what if not AI' trade with better timing. Weight-loss drugs are the strongest near-term catalyst, with the GLP-1 theme now topping UBS's ranking of investment themes in both the United States and Europe, and the bank flagged the start of Medicare coverage on 1 July as the next test of demand. UBS favours patent-light compounders such as Merck KGaA and Galderma, and among larger companies it prefers AstraZeneca and Roche, while it was more cautious on Novartis and Sanofi.
Sanofi Appoints Paulo Fontoura as Global Head of R&D Pharma
Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective September 1. Based in Paris, Fontoura will join the Executive Committee and report to CEO Belen Garijo, overseeing the company's end-to-end innovation engine from research through regulatory affairs. He succeeds Dr. Houman Ashrafian, who is leaving the company. The appointment comes as Sanofi drives an R&D transformation and advances a pipeline of new medicines across multiple therapeutic areas.
Adocia regains global rights to M1Pram as Sanofi exclusivity expires
Adocia announced the expiration of Sanofi's three-year exclusive right to negotiate a partnership for M1Pram, a fixed combination of insulin and amylin analogs for type 1 diabetes. The exclusivity was granted in July 2023 in return for a payment of €10 million. Adocia now retains global rights to M1Pram and has put its development on hold while it evaluates the path forward as the type 1 diabetes treatment landscape evolves. The company is focusing on its metabolic peptide delivery platforms, particularly BioChaperone. In a Phase 2a trial, M1Pram demonstrated a significant reduction in body weight of 5.56 kg for participants with a BMI over 30 kg/m² after 16 weeks compared to insulin lispro, along with a 21% reduction in prandial insulin doses while maintaining glycemic control without increasing hypoglycemia risk.
Kymera Therapeutics Stock Surges 51% Year to Date on KT-621 Progress
Kymera Therapeutics shares have risen 50.9% year to date, driven by rapid advancement of its lead candidate KT-621 for atopic dermatitis. The company completed enrollment in the phase IIb BROADEN2 study roughly six months ahead of schedule, pulling forward pivotal efficacy data to late 2026. Positive phase Ib data presented at the American Academy of Dermatology showed robust STAT6 degradation and a favorable safety profile, supporting KT-621 as a potential oral alternative to injectable biologics. Beyond KT-621, pipeline momentum includes dosing the first participant in a phase I trial of KT-485 under a Sanofi collaboration that triggered a $20 million milestone, new preclinical data for KT-579 in lupus models, and Gilead’s option exercise on KT-200 that brought a $45 million payment. Kymera plans to begin phase III studies in atopic dermatitis by mid-2027 and expects asthma data from the BREADTH trial in late 2027.
Sanofi's Nexviazyme meets all endpoints in infantile-onset Pompe disease study
Sanofi announced that the phase III Baby-COMET study evaluating Nexviazyme in patients with infantile-onset Pompe disease met all primary and secondary endpoints. The primary endpoint showed that treatment-naïve pediatric participants aged six months and younger remained alive and free of invasive ventilator support after 52 weeks of treatment. Secondary endpoints included the proportion of participants alive and free of invasive ventilation at 12 and 18 months of age, as well as improvements in other measures of disease progression. Based on this data, Sanofi plans to submit a regulatory filing in the United States seeking approval for Nexviazyme in infantile-onset Pompe disease in the second half of 2026. Nexviazyme is currently approved in the US for late-onset Pompe disease in patients aged one year and above, and is marketed as Nexviadyme in Europe where it is approved for both forms.
EIB grants Orano a €125 million loan for Orano Med’s cancer therapy infrastructure
The European Investment Bank has signed a €125 million credit line with Orano to finance the development of Orano Med and its industrial infrastructure, including the construction of the Advanced Thorium Extraction Facility in Bessines-sur-Gartempe, France. Orano Med, a subsidiary of the Orano group, develops lead-212-based targeted alpha therapies for cancer, with a clinical pipeline of four programs and partnerships with Sanofi, Roche, and Molecular Partners. The ATEF facility is described as the world’s first industrial site for large-scale production of thorium-228, a precursor of lead-212, and will supply all of Orano Med’s pharmaceutical production sites known as ATLabs. This is the second EIB loan to Orano in just over a year, following a €400 million agreement in March 2025 for the Georges Besse 2 uranium enrichment plant expansion.
Sanofi makes Q2 2026 aide-mémoire available ahead of July 30 results
Sanofi announced the availability of its aide-mémoire for the second quarter of 2026 results on the Investors page of sanofi.com. Prepared each quarter, the document supports financial modelling by covering non-comparable items, foreign currency impact, and share count. Sanofi's Q2 2026 results will be published on July 30, 2026.
Sanofi Stock May Be Undervalued as Fresh Drug Approvals Emerge
Sanofi's stock may be undervalued following recent drug approvals, with its price-to-earnings ratio of 18.7 times sitting below the pharmaceutical industry average of 20.7 times and a modelled fair P/E of 34.2 times. The company has secured approvals for therapies including Wayrilz, Cenrifki and Tzield, which could support future cash flows, though an ongoing European Commission antitrust probe into flu vaccine marketing presents regulatory risk. A bull case sees the stock as 22% undervalued, citing a strong pipeline with multiple Phase III readouts through 2026 and expansion of biologics like Dupixent, while a bear case flags heavy reliance on Dupixent, which generated €15.7 billion in annual sales, as a concentration risk. The stock has declined around 11.8% over the past three years, and the key question is whether the current discount reflects genuine upside or well-founded caution.
Sanofi faces EU antitrust probe while Nexviazyme trial delivers positive data
The European Commission has opened a formal antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine in the European Economic Area. Separately, Sanofi reported positive phase 3 top-line results for Nexviazyme in infants with infantile-onset Pompe disease, data that may support a future U.S. regulatory submission in this rare pediatric indication. The antitrust case focuses on compliance and commercial practices, while the rare disease data adds a new data point to the pipeline.
Warm Autoimmune Hemolytic Anemia Market to Grow at 14.4% CAGR Through 2036 on Novel Therapies
The warm autoimmune hemolytic anemia treatment market across the seven major markets is projected to grow at a compound annual growth rate of 14.4 percent from 2026 to 2036, driven by emerging targeted therapies. The total market size in the seven major markets was approximately 600 million US dollars in 2025, with the United States accounting for about 60 percent of that figure. In 2025, the total number of diagnosed prevalent cases of autoimmune hemolytic anemia across the seven major markets was estimated at approximately 120,000. Key pipeline candidates include Johnson & Johnson's IMAAVY, Sanofi's WAYRILZ, and Novartis' ianalumab, which are in late-stage development and target distinct immunologic pathways. The report notes that no therapies have yet received specific regulatory approval for warm autoimmune hemolytic anemia, creating a significant market opportunity for these novel agents.
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger
Talawar Therapeutics will debut on Nasdaq under the ticker TLWR after a business combination with JATT II Acquisition, raising $285 million to advance its lead candidate TALA-125 as a challenger to Sanofi and Regeneron's Dupixent in atopic dermatitis. The company secured $225 million through a private investment in public equity from investors including Access Biotechnology, Bain Capital Life Sciences, and RA Capital Management, which together with $60 million held in JATT II's trust account—assuming no redemptions—will fund a Phase IIb proof-of-concept trial for the IL-13/IL-18 bispecific antibody, with a readout expected in the second half of 2028. TALA-125 is expected to enter the clinic in the first quarter of 2027, with an interim data readout in the fourth quarter, and Talawar is also developing two discovery-phase immunology programs, TALA-307 and TALA-711. The transaction is expected to close in the second half of 2026, making Talawar the first spinout from British biotech builder Khanda Therapeutics. The atopic dermatitis market across the seven major markets is projected to reach $22.4 billion in 2033, but Talawar will face competition from established therapies like Dupixent and AbbVie's Rinvoq, as well as more than 200 active clinical trials for investigational drugs.
Deutsche Bank Cuts Sanofi Price Target to EUR 95, Maintains Buy Rating
Deutsche Bank lowered its price target on Sanofi to EUR 95 from EUR 100 while keeping a Buy rating on the shares. The adjustment follows Sanofi's fiscal first-quarter 2026 results, which showed double-digit sales and business earnings per share growth. Sales rose 13.6 percent at constant exchange rates, and business earnings per share reached 1.88 euros. Pharma launches sales surged 49.6 percent to 1.2 billion euros, driven by Ayvakit, ALTUVIIIO, and Sarclisa, while Dupixent sales grew 30.8 percent to 4.2 billion euros.
BofA Expects Positive Investor Reaction to Sanofi R&D Leadership Change
Bank of America expects a positive investor reaction to Sanofi's appointment of Dr. Paulo Fontoura as its new Executive Vice President, Global Head of Research & Development Pharma, effective September 1. Analyst Sachin Jain noted the leadership change is likely to be viewed favorably given Sanofi's recent R&D setbacks, though he highlighted Dr. Fontoura's mixed track record from his time at Roche and said revitalizing the R&D organization will be a multi-year project. BofA maintains a Neutral rating and €92 price target on Sanofi, implying nearly 25% upside.
Sanofi Faces EU Probe Over Alleged Flu-Vaccine Disparagement
European Commission regulators have opened an investigation into Sanofi over concerns it may have illegally disparaged CSL Seqirus' Fluad flu vaccine to boost sales of its own Efluelda jab. The probe focuses on whether Sanofi ran a misleading communication campaign aimed at healthcare professionals in Germany and France, including claims that Fluad had a weaker evidentiary basis than Efluelda. The investigation follows secret raids at Sanofi sites in Germany and France last September. Sanofi said it is confident it has acted in full compliance with all applicable laws and is cooperating fully with regulators. If a breach is found, penalties could reach as high as 10% of annual global revenue, though fines rarely reach that level.
AbbVie to acquire Apogee Therapeutics for $10.9 billion in cash
AbbVie announced a planned $10.9 billion acquisition of Apogee Therapeutics, paying $135.11 per share in cash, a 49% premium to Apogee's closing price last week. The deal brings zumilokibart, a promising immunology drug targeting IL-13, into AbbVie's pipeline, positioning it to compete with Regeneron and Sanofi's Dupixent in atopic dermatitis and asthma. AbbVie will fund the acquisition entirely with operating cash flows without adding debt, and the company noted the transaction is not expected to be accretive to adjusted earnings per share until 2032. AbbVie reported first-quarter revenue of $15 billion, up 12% year over year, and raised its full-year adjusted EPS guidance to a range of $14.08 to $14.28. The deal is seen as a strategic move to bolster AbbVie's immunology platform with next-generation, longer-dosing-interval therapies.
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs
The chronic spontaneous urticaria market across the seven major markets reached approximately 2 billion dollars in 2025, with the United States holding the largest share. Total diagnosed prevalent cases of chronic urticaria in those markets were about 4.8 million in 2025 and are expected to rise by 2036. Key companies advancing new therapies include Celldex Therapeutics, Sanofi, Jasper Therapeutics, Evommune, Blueprint Medicines, ARS Pharmaceuticals, Nurix Therapeutics, InflaRx, and Otsuka Holdings through Taiho Pharmaceutical. Promising pipeline candidates such as barzolvolimab, rilzabrutinib, briquilimab, EVO756, BLU-808, ARS-1, bexobrutideg, INF904, and TAS5315 are in clinical development, while recent approvals of DUPIXENT and RHAPSIDO have already broadened treatment options beyond traditional anti-IgE biologics.
Sanofi Secures EU and Japan Approvals for Two BTK Inhibitors
Sanofi has obtained European Union approval for Cenrifki, or tolebrutinib, to treat non-relapsing secondary progressive multiple sclerosis, and Japanese approval for Wayrilz, or rilzabrutinib, for persistent or chronic immune thrombocytopenia. These back-to-back regulatory wins expand the company's Bruton's tyrosine kinase inhibitor footprint across neurology and rare hematology, reinforcing its pivot toward higher-value specialty medicines. The Cenrifki approval adds a first-in-class, disability-focused multiple sclerosis medicine in Europe, while the Wayrilz green light in Japan marks progress in a rare blood disorder. The developments provide tangible evidence of pipeline execution as Sanofi works to offset pricing pressure in vaccines and upcoming patent expiries on key drugs like Dupixent.
EU Clears Sanofi's Cenrifki as First Disability-Targeting Drug for Non-Relapsing SPMS
The European Commission has approved Sanofi's Bruton's tyrosine kinase inhibitor Cenrifki, or tolebrutinib, for adults with secondary progressive multiple sclerosis who have not had relapses in the past two years. Cenrifki becomes the first disability-targeting medicine cleared in the EU for SPMS without relapses. Sanofi plans to launch the drug in Germany later this year with support programs in place. The approval was based on the phase III HERCULES study, which showed Cenrifki significantly delayed disability progression in non-relapsing SPMS, along with supporting data from the GEMINI 1 and GEMINI 2 studies in relapsing MS. The FDA issued a complete response letter for tolebrutinib in non-relapsing SPMS in December 2025.